ES2169690B1 - Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen. - Google Patents

Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen.

Info

Publication number
ES2169690B1
ES2169690B1 ES200002414A ES200002414A ES2169690B1 ES 2169690 B1 ES2169690 B1 ES 2169690B1 ES 200002414 A ES200002414 A ES 200002414A ES 200002414 A ES200002414 A ES 200002414A ES 2169690 B1 ES2169690 B1 ES 2169690B1
Authority
ES
Spain
Prior art keywords
ethyl
excitotox
alquilglicina
aggressions
quarters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200002414A
Other languages
English (en)
Other versions
ES2169690A1 (es
Inventor
Vicente Felipo
Carmina Montoliu
Montiel Antonio Ferrer
Cases Rosa Planells
Fernandez Jaime M Merino
Paya Enrique Perez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DiverDrugs SL
Original Assignee
DiverDrugs SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200002414A priority Critical patent/ES2169690B1/es
Application filed by DiverDrugs SL filed Critical DiverDrugs SL
Priority to AU2001291906A priority patent/AU2001291906B2/en
Priority to AU9190601A priority patent/AU9190601A/xx
Priority to PT01972113T priority patent/PT1338604E/pt
Priority to MXPA03003157A priority patent/MXPA03003157A/es
Priority to BR0114660-2A priority patent/BR0114660A/pt
Priority to PCT/ES2001/000369 priority patent/WO2002028885A1/es
Priority to ES01972113T priority patent/ES2267816T3/es
Priority to EP01972113A priority patent/EP1338604B9/en
Priority to DE60121464T priority patent/DE60121464T2/de
Priority to US10/398,467 priority patent/US6992064B2/en
Priority to DK01972113T priority patent/DK1338604T3/da
Priority to JP2002532467A priority patent/JP3925712B2/ja
Priority to CA2427072A priority patent/CA2427072C/en
Priority to KR1020037004884A priority patent/KR100849739B1/ko
Priority to AT01972113T priority patent/ATE332913T1/de
Publication of ES2169690A1 publication Critical patent/ES2169690A1/es
Application granted granted Critical
Publication of ES2169690B1 publication Critical patent/ES2169690B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Trímeros de n-alquilglicinas capaces de proteger a neuronas contra agresiones excitotóxicas, y composiciones que los contienen. Los trímeros de N-alquilglicina (I), donde R1, R2 y R3, independientemente entre sí, se seleccionan entre ciclopropilo, sec-butilo, 2-metoxietilo, 3-metilbutilo, ciclohexilo, 2- (N-pirrolidinil) etilo, 2- (metilcarbonilamino) etilo, 3- (2-oxo-N-pirrolidinil) propilo, 2- (2- piridil) etilo, 2-feniletilo, 2- (2-tetrahidrofuril) etilo, 2- (N- imidazolil) etilo, 2- (4-metoxifenil) etilo, 2- (3,4- dimetoxifenil) etilo, 2- (2,4-diclorofenil) etilo, 2- [2- (N- metil) pirrolidinil] etilo, 2- (4-aminosulfonilfenil) etilo, 2- (morfolino) etilo, 3- (N,N-dietilamino) propilo, 3,3-difenil- propilo, 3- (N,N-dimetilamino) propilo, y 2- (N,N-dietilamino) etilo, son capaces de bloquear los receptores de L-glutamato, y son adecuados para tratar trastornos mediados por dichos receptores.
ES200002414A 2000-10-06 2000-10-06 Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen. Expired - Fee Related ES2169690B1 (es)

Priority Applications (16)

Application Number Priority Date Filing Date Title
ES200002414A ES2169690B1 (es) 2000-10-06 2000-10-06 Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen.
US10/398,467 US6992064B2 (en) 2000-10-06 2001-10-05 N-alkylglycine trimeres capable of protecting neurons against excitotoxic aggressions and compositions containing such trimeres
PT01972113T PT1338604E (pt) 2000-10-06 2001-10-05 Trímeros de n-alquilglicina com a capacidade de proteger os neurónios contra as agressões excitotóxicas e composições contendo os ditos trímeros
MXPA03003157A MXPA03003157A (es) 2000-10-06 2001-10-05 Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitoxicas y composiciones que lo contienen.
BR0114660-2A BR0114660A (pt) 2000-10-06 2001-10-05 Trìmeros de n-alquilglicina capazes de proteger os neurÈnios contra agressões excitotóxicas e composições que os contêm
PCT/ES2001/000369 WO2002028885A1 (es) 2000-10-06 2001-10-05 Trímeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotóxicas, y composiciones que los contienen
ES01972113T ES2267816T3 (es) 2000-10-06 2001-10-05 Trimeros de n-alquilglicina que pueden proteger neuronas frente a agresiones excitotoxicas y composiciones que contienen dichos trimeros.
EP01972113A EP1338604B9 (en) 2000-10-06 2001-10-05 N-alkylglycine trimeres capable of protecting neurons against excitotoxic aggressions and compositions containing said trimeres
AU2001291906A AU2001291906B2 (en) 2000-10-06 2001-10-05 N-alkylglycine trimeres capable of protecting neurons against excitotoxic aggressions and compositions containing said trimeres
AU9190601A AU9190601A (en) 2000-10-06 2001-10-05 N-alkylglycine trimeres capable of protecting neurons against excitotoxic aggressions and compositions containing said trimeres
DK01972113T DK1338604T3 (da) 2000-10-06 2001-10-05 N-Alkylglycintrimerer i stand til beskyttelse af neuroner mod excitotoksiske aggressioner og sammensætninger indeholdende de nævnte trimerer
JP2002532467A JP3925712B2 (ja) 2000-10-06 2001-10-05 興奮性侵襲に対するニューロンの保護が可能なｎ−アルキルグリシン三量体および該三量体を含有する組成物
CA2427072A CA2427072C (en) 2000-10-06 2001-10-05 N-alkylglycine trimers capable of protecting neurons against excitotoxic aggressions and compositions containing said trimers
KR1020037004884A KR100849739B1 (ko) 2000-10-06 2001-10-05 흥분독소 공격에 대하여 신경을 보호하는 능력을 갖는 ｎ-알킬글리신 트리머 및 그 트리머를 포함하는 조성물
AT01972113T ATE332913T1 (de) 2000-10-06 2001-10-05 N-alkylglycintrimeres, das dazu in der lage ist, neuronen gegen excitotoxische aggressionen zu schützen, und zusammensetzungen, die dieses trimere enthalten
DE60121464T DE60121464T2 (de) 2000-10-06 2001-10-05 N-alkylglycintrimeres, das dazu in der lage ist, neuronen gegen excitotoxische aggressionen zu schützen, und zusammensetzungen, die dieses trimere enthalten

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200002414A ES2169690B1 (es) 2000-10-06 2000-10-06 Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen.

Publications (2)

Publication Number Publication Date
ES2169690A1 ES2169690A1 (es) 2002-07-01
ES2169690B1 true ES2169690B1 (es) 2004-03-16

Family

ID=8495179

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200002414A Expired - Fee Related ES2169690B1 (es) 2000-10-06 2000-10-06 Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen.
ES01972113T Expired - Lifetime ES2267816T3 (es) 2000-10-06 2001-10-05 Trimeros de n-alquilglicina que pueden proteger neuronas frente a agresiones excitotoxicas y composiciones que contienen dichos trimeros.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01972113T Expired - Lifetime ES2267816T3 (es) 2000-10-06 2001-10-05 Trimeros de n-alquilglicina que pueden proteger neuronas frente a agresiones excitotoxicas y composiciones que contienen dichos trimeros.

Country Status (14)

Country Link
US (1) US6992064B2 (es)
EP (1) EP1338604B9 (es)
JP (1) JP3925712B2 (es)
KR (1) KR100849739B1 (es)
AT (1) ATE332913T1 (es)
AU (2) AU9190601A (es)
BR (1) BR0114660A (es)
CA (1) CA2427072C (es)
DE (1) DE60121464T2 (es)
DK (1) DK1338604T3 (es)
ES (2) ES2169690B1 (es)
MX (1) MXPA03003157A (es)
PT (1) PT1338604E (es)
WO (1) WO2002028885A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2296484A1 (es) * 2005-11-23 2008-04-16 Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%) Composicion farmaceutica para inhibir apoptosis.

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050123162A (ko) * 2003-04-15 2005-12-29 메르크 파텐트 게엠베하 세포자멸사 유도를 위한 ｎ-알킬글리신 삼량체의 규명
ATE556067T1 (de) 2003-05-20 2012-05-15 Ajinomoto Kk Modulatoren des vanilloid rezeptors
ES2293834B1 (es) 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
WO2010098843A2 (en) 2009-02-24 2010-09-02 New York University Peptoid oligomers, pharmaceutical compositions and methods of using the same
EP2289886A1 (en) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments
WO2011156003A2 (en) 2010-06-09 2011-12-15 New York University Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same
HUE029393T2 (en) * 2010-08-31 2017-03-28 Bionure Farma S L Neurotrophin receptor agonists and their use as medicaments
US20120089291A1 (en) * 2010-10-12 2012-04-12 Halder Bibhrajit Autonomous machine control system
WO2017066454A2 (en) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions and methods for reducing ice crystal formation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747458A (en) * 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands
US6391871B1 (en) * 1996-09-20 2002-05-21 John W. Olney Preventing neuronal degeneration in Alzheimer's disease
DE19751062A1 (de) * 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
US6124361A (en) * 1997-12-31 2000-09-26 Pfizer Inc Bicyclo[3.1.0]hexanes and related compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2296484A1 (es) * 2005-11-23 2008-04-16 Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%) Composicion farmaceutica para inhibir apoptosis.

Also Published As

Publication number Publication date
CA2427072C (en) 2011-03-22
US6992064B2 (en) 2006-01-31
BR0114660A (pt) 2003-07-01
KR20030081313A (ko) 2003-10-17
US20040029811A1 (en) 2004-02-12
EP1338604B9 (en) 2008-07-09
CA2427072A1 (en) 2003-04-04
JP3925712B2 (ja) 2007-06-06
PT1338604E (pt) 2006-12-29
AU2001291906B2 (en) 2007-05-31
JP2004510782A (ja) 2004-04-08
EP1338604A1 (en) 2003-08-27
ES2169690A1 (es) 2002-07-01
EP1338604B1 (en) 2006-07-12
KR100849739B1 (ko) 2008-08-01
ES2267816T3 (es) 2007-03-16
DE60121464D1 (de) 2006-08-24
MXPA03003157A (es) 2004-12-06
WO2002028885A1 (es) 2002-04-11
DE60121464T2 (de) 2007-04-12
DK1338604T3 (da) 2006-11-06
ATE332913T1 (de) 2006-08-15
AU9190601A (en) 2002-04-15

Similar Documents

Publication Publication Date Title
ES2169690B1 (es) Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen.
DK0957099T3 (da) Heterocykliske carboxamider
HUS1600017I1 (hu) (2S)-2-[2-oxo-4-propilpirrolidinil]-butánamid (4R) és (4S) diasztereoizomerjei és gyógyszerészetileg elfogadható sói és ezek gyógyászati alkalmazása
ES2172585T3 (es) Derivado de benzoimidazol.
NI200600136A (es) Derivados de 3-clicloalquilaminopirrolidina como moduladores de receptores de quimiocina.
DE60037892D1 (de) Nitroimidazolpräparationen zur äusseren anwendung zur behandlung von atopischer dermatitis
DE69433181D1 (de) 5-(2-imidazolinylamino)benzimidazol derivate, deren herstellung und deren verwendung als alpha-2-adrenoceptor agonisten
AR022019A1 (es) Un compuesto de imidazol y las composiciones farmaceuticas que lo contienen
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
MX9307332A (es) 3-(aminoalquilamino)-1,2-bencisoxasoles substituidos y compuestos relacionados.
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
DE69323667D1 (de) 4-substituierte 1,2,4-Triazolderivate
NO20035012L (no) Anvendelse av triazolopyrimidinderivater som mikrobicider for beskyttelse av materialer
ATE273970T1 (de) N-acyl und n-aroyl aralkylamide
DE69708968D1 (de) Arylacrylamidderivate als 5HT1 Agoniste oder Antagoniste
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
ATE307851T1 (de) Eine vernetzbare polyethylen-zusammensetzung
ES2188282T3 (es) Compuestos de 3-(fenilo sustituido)-5-tienil-1,2,4-triazol con actividad contra la mosca blanca.
CO5031327A1 (es) Mezclas fungicidas que comprenden un carbamato y 4-(2-metil- 3-(4-terc-butilfenil)-propil)-2,6 dimetil morfolina o 4-(c10 c13-alquil)-2,6-dimetilmorfolina o (rs)-1-(3-(4-terc-butilfe nil)-2-metilpropil)-piperidina y una sustancia activa del grupo de
ES2140897T3 (es) Mezclas fungicidas.
ES2152319T3 (es) Derivado del benceno util contra isquemias.
ATE282315T1 (de) Synergistische biozide wirkstoffkombinationen, tetramethylolacetylendiharnstoff und ein isothiazoline-3-on enthaltend, und verwendungen solcher wirkstoffkombinationen als konservierungsmittel
DE69504272D1 (de) N-Arylthiohydrazon-Derivate als insektizide und akarazide Mittel
DK0821955T3 (da) Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse
DE69620573D1 (de) Mittel zur verminderung des augeninnendrucks

Legal Events

Date Code Title Description
PC2A Transfer of patent
EC2A Search report published

Date of ref document: 20020701

Kind code of ref document: A1

Effective date: 20020701

FG2A Definitive protection

Ref document number: 2169690B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807